Ingrid Zhang, CEO of Legend Biotech Corp (NASDAQ: LEGN), purchased 20,000 ordinary shares on November 17, 2026, at $8.16 per share for a total of $163,200. This equals a converted price of $16.32 per American Depositary Share, with each ADS representing two ordinary shares. Zhang now directly holds 1,151,860 ordinary shares following the acquisition.
The purchase occurs as LEGN trades at $15.25, near its 52-week low of $15.14, after declining nearly 46% over the past year.
Legend Biotech reported third-quarter 2026 revenue of $359.5 million, slightly beating Wall Street expectations of $358.63 million. The company posted a loss per share of $0.13, missing the forecast loss of $0.0037. CARVYKTI net trade sales rose 36% year-over-year to $710 million in the quarter. The company raised its fourth-quarter product gross-margin outlook to the high-50% range.
H.C. Wainwright reiterated a Buy rating with a $65.00 price target. The firm noted Legend's progress in reaching half of U.S. Carvykti apheresis for second- and third-line patients.
Investors monitoring LEGN should track fourth-quarter results and gross-margin delivery against the raised guidance.